A. Meyer, N. Meyer, M. Schaeffer, J. Gottenberg, B. Geny et al., Incidence and prevalence of inflammatory myopathies: a systematic review, Rheumatol Oxf Engl, vol.54, issue.1, pp.50-63, 2015.

A. Bohan and J. B. Peter, Polymyositis and dermatomyositis (first of two parts), N Engl J Med, vol.292, issue.7, pp.344-351, 1975.

A. Bohan and J. B. Peter, Polymyositis and dermatomyositis (second of two parts), N Engl J Med, vol.292, issue.8, pp.403-410, 1975.

S. Carpenter, G. Karpati, I. Heller, and A. Eisen, Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy, Neurology, vol.28, issue.1, pp.8-17, 1978.

P. H. Plotz, M. Dalakas, R. L. Leff, L. A. Love, F. W. Miller et al., Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders, Ann Intern Med, vol.111, issue.2, pp.143-57, 1989.

L. A. Love, R. L. Leff, D. D. Fraser, I. N. Targoff, M. Dalakas et al., A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore), vol.70, pp.360-74, 1991.

Y. Troyanov, I. N. Targoff, J. Tremblay, J. Goulet, Y. Raymond et al., Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients, Medicine, 2005.

J. E. Hoogendijk, A. A. Amato, B. R. Lecky, E. H. Choy, I. E. Lundberg et al., 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, Neuromuscul Disord NMD, vol.14, issue.5, pp.337-382, 2003.

A. Meyer, B. Lannes, J. Goetz, A. Echaniz-laguna, D. Lipsker et al., Inflammatory myopathies: A new landscape, Joint Bone Spine, vol.85, issue.1, pp.23-33, 2018.

I. E. Lundberg, A. Tjärnlund, M. Bottai, V. P. Werth, C. Pilkington et al.,

, European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups, Ann Rheum Dis, vol.76, issue.12, pp.1955-64, 2017.

G. S. Cooper, M. Bynum, and E. C. Somers,

, Autoimmune Diseases: Improved Prevalence Estimates and Understanding of Clustering of Diseases, J Autoimmun, vol.33, issue.3-4, pp.197-207, 2009.

B. Dahlbäck, Coagulation and inflammation-close allies in health and disease, Semin Immunopathol, vol.34, issue.1, pp.1-3, 2012.

C. T. Esmon and N. L. Esmon, The link between vascular features and thrombosis, Annu Rev Physiol, vol.73, pp.503-517, 2011.

S. P. Ardoin, J. C. Shanahan, and D. S. Pisetsky, The role of microparticles in inflammation and thrombosis, Scand J Immunol, vol.66, issue.2-3, pp.159-65, 2007.

C. T. Esmon, Inflammation and the activated protein C anticoagulant pathway, Semin Thromb Hemost, vol.32, issue.1, pp.49-60, 2006.

S. V. Ramagopalan, C. J. Wotton, A. E. Handel, D. Yeates, and M. J. Goldacre, Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study, BMC Med, vol.9, p.1, 2011.

B. Zöller, X. Li, J. Sundquist, and K. Sundquist, Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden, Lancet Lond Engl, vol.379, issue.9812, pp.244-253, 2012.

S. A. Johannesdottir, M. Schmidt, E. Horváth-puhó, and H. T. Sørensen, Autoimmune skin and connective tissue diseases and risk of venous thromboembolism: a population-based casecontrol study, J Thromb Haemost JTH, vol.10, issue.5, pp.815-836, 2012.

W. Chung, C. Lin, F. Sung, C. Lu, and C. Kao, Increased risk of venous thromboembolism in patients with dermatomyositis/polymyositis: a nationwide cohort study, Thromb Res, vol.134, issue.3, pp.622-628, 2014.

E. C. Carruthers, H. K. Choi, E. C. Sayre, and J. A. Aviña-zubieta, Risk of Deep Venous Thrombosis and Pulmonary Embolism in Individuals with Polymyositis and Dermatomyositis: A General Population-Based Study, Ann Rheum Dis, vol.75, issue.1, p.110, 2016.

A. Antovic, A. Notarnicola, J. Svensson, I. E. Lundberg, and M. Holmqvist, Venous thromboembolic events in idiopathic inflammatory myopathy-occurrence and relation to disease onset, Arthritis Care Res, 2018.

N. Bleau, V. Patenaude, and H. A. Abenhaim, Risk of Venous Thromboembolic Events in Pregnant Patients With Autoimmune Diseases: A Population-Based Study, Clin Appl Thromb Off J Int Acad Clin Appl Thromb, vol.22, issue.3, pp.285-91, 2016.

S. D. Gaitonde and S. P. Ballou, Deep venous thrombosis in dermatomyositis, J Rheumatol

A. Selva-o'callaghan, A. Fernández-luque, X. Martínez-gómez, A. Labirua-iturburu, and M. Vilardell-tarrés, Venous thromboembolism in patients with dermatomyositis and polymyositis, Clin Exp Rheumatol, vol.29, issue.5, pp.846-855, 2011.

M. Nowak, K. Królak-nowak, A. Sobolewska-w?odarczyk, J. Fichna, and M. W?odarczyk, Elevated risk of venous thromboembolic events in patients with inflammatory myopathies. Vasc Health Risk Manag, vol.12, pp.233-241, 2016.

Y. Li, P. Wang, L. Li, F. Wang, and Y. Liu, Increased risk of venous thromboembolism associated with polymyositis and dermatomyositis: a meta-analysis, Ther Clin Risk Manag, vol.14, pp.157-65, 2018.

C. L. Hill, Y. Zhang, B. Sigurgeirsson, E. Pukkala, L. Mellemkjaer et al., Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study, Lancet Lond Engl, vol.357, issue.9250, pp.96-100, 2001.

S. A. Johannesdottir, E. Horváth-puhó, O. M. Dekkers, S. C. Cannegieter, J. Jørgensen et al., Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study, JAMA Intern Med, vol.173, issue.9, pp.743-52, 2013.

S. Couray-targe, R. Ecochard, and C. C. , Program for medicalization of the information systems in France: tool for management and quality assessment?

, Presse Medicale Paris Fr, vol.28, pp.1597-603, 1983.

J. B. Lilleker, J. Vencovsky, G. Wang, L. R. Wedderburn, L. P. Diederichsen et al., The EuroMyositis registry: an international collaborative tool to facilitate myositis research, Ann Rheum Dis, vol.77, issue.1, pp.30-39, 2018.

H. Miller, A. Parton, M. Holton, J. Sewry, C. Hanna et al., Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, vol.20, pp.142-149, 2008.

R. C. Griggs, V. Askanas, S. Dimauro, A. Engel, G. Karpati et al., Inclusion body myositis and myopathies, Ann Neurol, vol.38, issue.5, pp.705-718, 1995.

J. Verschuuren, U. Badrising, A. Wintzen, B. Van-engelen, H. Van-der-hoeven et al., Inclusion body myositis, Diagnostic criteria for neuromuscular disorders, pp.81-85, 1997.

Y. Allenbach, L. Arouche-delaperche, C. Preusse, H. Radbruch, G. Butler-browne et al., Necrosis in anti-SRP+and anti-HMGCR+myopathies: Role of autoantibodies and complement, Neurology, vol.90, issue.6, pp.507-524, 2018.

G. R. Connors, L. Christopher-stine, C. V. Oddis, and S. K. Danoff, Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest, vol.138, pp.1464-74, 2010.

M. Petri, A. Orbai, G. S. Alarcón, C. Gordon, J. T. Merrill et al., Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus, 37. van den Hoogen F, vol.64, pp.2677-86, 2012.

. Rheumatology/european, League against Rheumatism collaborative initiative, Arthritis Rheum, vol.65, issue.11, pp.2737-2784, 2013.

D. Aletaha, T. Neogi, A. J. Silman, J. Funovits, D. T. Felson et al., , 2010.

, Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative, Arthritis Rheum, vol.62, issue.9, pp.2569-81, 2010.

C. H. Shiboski, S. C. Shiboski, R. Seror, L. A. Criswell, M. Labetoulle et al.,

, American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts, Ann Rheum Dis, 2017.

R. Kasukawa and G. C. Sharp, Mixed Connective Tissue Disease and Anti-Nuclear Antibodies, Proceedings of the International Symposium on Mixed Connective Tissue Disease and Anti-Nuclear Antibodies, vol.378, pp.29-30, 1986.

J. M. Amigues, A. Cantagrel, M. Abbal, and B. Mazieres, Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies

, Autoimmunity Group of the Hospitals of Toulouse, J Rheumatol, vol.23, issue.12, pp.2055-62, 1996.

S. Jablonska and M. Blaszczyk, Scleromyositis: a scleroderma/polymyositis overlap syndrome, Clin Rheumatol, vol.17, issue.6, pp.465-472, 1998.

S. Jablonska and M. Blaszczyk, Scleroderma overlap syndromes, Adv Exp Med Biol, vol.455, pp.85-92, 1999.

L. Török, K. Dankó, G. Cserni, and G. Szûcs, PM-SCL autoantibody positive scleroderma with polymyositis (mechanic's hand: clinical aid in the diagnosis), J Eur Acad Dermatol Venereol JEADV, vol.18, issue.3, pp.356-365, 2004.

S. Hoa, M. Hudson, Y. Troyanov, S. Proudman, J. Walker et al., Singlespecificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations. Medicine (Baltimore), vol.95, p.4713, 2016.

J. Lega, N. Fabien, Q. Reynaud, I. Durieu, S. Durupt et al., The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome, Autoimmun Rev, vol.13, issue.9, pp.883-91, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02046821

C. Belizna, D. Henrion, A. Beucher, C. Lavigne, A. Ghaali et al., Anti-Ku antibodies: Clinical, genetic and diagnostic insights, Autoimmun Rev, vol.9, issue.10, pp.691-695, 2010.

A. Compston, Medical Research Council: Nerve Injuries Research Committee. His Majesty's Stationery Office: 1942; pp. 48 (iii) and 74 figures and 7 diagrams; with Aids to the Examination of the Peripheral Nervous System. By Michael O'Brien for the Guarantors of Brain, Brain, vol.133, issue.10, pp.2838-2882, 2010.

M. Mahler, F. W. Miller, and M. J. Fritzler, Idiopathic inflammatory myopathies and the antisynthetase syndrome: a comprehensive review, Autoimmun Rev, vol.13, issue.4-5, pp.367-71, 2014.

E. Bartoloni, M. A. Gonzalez-gay, C. Scirè, S. Castaneda, R. Gerli et al., Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study, Autoimmun Rev, vol.16, issue.3, pp.253-260, 2017.

A. B. Robinson and A. M. Reed, Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis, Nat Rev Rheumatol, vol.7, issue.11, pp.664-75, 2011.

M. W. So, B. S. Koo, Y. Kim, C. Lee, and B. Yoo, Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis, J Rheumatol, vol.38, issue.11, pp.2432-2437, 2011.

R. Neri, S. Barsotti, B. Simone, V. Iacopetti, G. Iacopetti et al., Cancerassociated myositis: a 35-year retrospective study of a monocentric cohort, Rheumatol Int, vol.34, issue.4, pp.565-574, 2014.

A. L. Mammen, T. Chung, L. Christopher-stine, P. Rosen, A. Rosen et al.,

, Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy, Arthritis Rheum, vol.63, issue.3, pp.713-734, 2011.

Ø. Molberg, C. Dobloug, I. Pinal-fernandez, C. Parks, J. L. Werner et al., Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle, Curr Opin Rheumatol, vol.28, issue.6, pp.263-70, 2016.

H. Chinoy, S. Adimulam, F. Marriage, P. New, M. Vincze et al., Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study, Ann Rheum Dis, 2011.

, Different Racial Groups Is Differentially Associated with the Development of Myositis Autoantibodies and Interstitial Lung Disease in the Idiopathic Inflammatory Myopathies

, Available from: http://acrabstracts.org/abstract/tobacco-smoking-in-different-racial-groups-isdifferentially-associated-with-the-development-of-myositis-autoantibodies-and-interstitiallung-disease-in-the-idiopathic-inflammatory-myopathies/ 59. Diederichsen LP. Cardiovascular involvement in myositis, ACR Meeting Abstracts, 2018.

C. Fernandez, N. Bardin, D. Paula, A. M. Salort-campana, E. Benyamine et al., Correlation of Clinicoserologic and Pathologic Classifications of Inflammatory Myopathies, Medicine, vol.92, issue.1, 2013.

F. A. Anderson, H. B. Wheeler, R. J. Goldberg, D. W. Hosmer, N. A. Patwardhan et al., A Population-Based Perspective of the Hospital Incidence and Case-Fatality Rates of Deep Vein Thrombosis and Pulmonary Embolism: The Worcester DVT Study, Arch Intern Med, vol.151, issue.5, pp.933-941, 1991.

J. A. Heit, M. D. Silverstein, D. N. Mohr, T. M. Petterson, W. M. O'fallon et al.,

, Predictors of Survival After Deep Vein Thrombosis and Pulmonary Embolism: A PopulationBased, Cohort Study, Arch Intern Med, vol.159, issue.5, pp.445-53, 1999.

R. L. Bick, Cancer-Associated Thrombosis, N Engl J Med, vol.10, issue.2, pp.109-120, 2003.

J. Xu, F. Lupu, and C. T. Esmon, Inflammation, innate immunity and blood coagulation

. Hamostaseologie, , vol.30, pp.5-6, 2010.

J. P. Scott and C. Arroyave, Activation of complement and coagulation in juvenile dermatomyositis, Arthritis Rheum, vol.30, issue.5, pp.572-578, 1987.

M. C. Dalakas, High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events, Neurology, vol.44, issue.2, pp.223-229, 1994.

M. Stangel, H. P. Hartung, P. Marx, and R. Gold, Side effects of high-dose intravenous immunoglobulins, Clin Neuropharmacol, vol.20, issue.5, pp.385-93, 1997.

B. Dahlbäck, A. Hillarp, S. Rosen, and B. Zöller, Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis, Ann Hematol, vol.72, issue.4, pp.166-76, 1996.

D. C. Rees, M. Cox, and J. B. Clegg, World distribution of factor V Leiden, Lancet Lond Engl

, Oct, vol.28, issue.8983, pp.1133-1137

J. A. Heit, J. L. Sobell, H. Li, and S. S. Sommer, The incidence of venous thromboembolism among Factor V Leiden carriers: a community-based cohort study, J Thromb Haemost JTH, vol.3, issue.2, pp.305-316, 2005.

S. R. Poort, F. R. Rosendaal, P. H. Reitsma, and R. M. Bertina, A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis, Blood, vol.88, issue.10, pp.3698-703, 1996.

R. F. Franco and P. H. Reitsma, Genetic risk factors of venous thrombosis, Hum Genet, 2001.

M. C. Pintao, D. D. Ribeiro, I. D. Bezemer, A. A. Garcia, M. Visser et al., Protein S levels and the risk of venous thrombosis: results from the MEGA case-control study, Blood, vol.122, issue.18, pp.3210-3219, 2013.

P. A. Merkel, Y. Chang, S. S. Pierangeli, K. Convery, E. N. Harris et al., The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases, Am J Med, vol.101, issue.6, pp.576-83, 1996.

Y. Sherer, A. Livneh, Y. Levy, Y. Shoenfeld, and P. Langevitz, Dermatomyositis and polymyositis associated with the antiphospholipid syndrome-a novel overlap syndrome, Lupus, vol.9, issue.1, pp.42-48, 2000.

G. François-devos, O. Leleu, A. P. Jounieaux, and V. , Bronchiolitis obliterans organizing pneumonia associated with dermatomyositis and antiphospholipid syndrome, Rev Mal Respir, vol.19, pp.249-51, 1921.

A. Ponyi, T. Constantin, and K. Dankó, Antiphospholipid and antisynthetase syndrome in a patient with polymyositis-rheumatoid arthritis overlap, Clin Rheumatol, vol.23, issue.4, pp.371-373, 2004.

A. Zubrzycka-sienkiewicz, T. Wagner, J. Zabek, and A. Palacz, Symptoms and signs of polymositis, systematic lupus erythematosus and antiphospholipid syndrome follow consecutively

, Pol Arch Med Wewn, vol.118, pp.80-84, 2008.

A. Mori, H. Nodera, S. Nakane, and R. Kaji, Transverse myelitis and polymyositis associated with antiphospholipid antibody syndrome, Clin Neurol Neurosurg, vol.112, issue.8, pp.713-719, 2010.

C. Wang, N. Wang, T. Lin, and C. Chen, Anti-Jo-1 myositis and the antiphospholipid syndrome showing right ventricular thrombus: a novel overlap syndrome with atypical presentation, Mod Rheumatol, vol.24, issue.5, pp.865-873, 2014.

I. D. Bezemer, F. Van-der-meer, J. Eikenboom, F. R. Rosendaal, and C. Doggen, The value of family history as a risk indicator for venous thrombosis, Arch Intern Med, vol.169, issue.6, pp.610-615, 2009.

P. Prandoni, M. H. Prins, A. Ghirarduzzi, V. Pengo, M. T. Sartori et al., Family history of venous thrombosis or sudden death as a risk factor for venous thromboembolism, Thromb Haemost, vol.107, issue.6, pp.1191-1193, 2012.

V. Vuong, T. A. Duong, J. Aouizerate, F. J. Authier, S. Ingen-housz-oro et al.,

L. Allanore, Dermatomyositis: factors predicting relapse, J Eur Acad Dermatol Venereol JEADV, vol.30, issue.5, pp.813-821, 2016.

Y. M. Maugars, J. M. Berthelot, A. A. Abbas, J. M. Mussini, J. M. Nguyen et al., Longterm prognosis of 69 patients with dermatomyositis or polymyositis, Clin Exp Rheumatol, vol.14, issue.3, pp.263-74, 1996.

I. Yamadori, J. Fujita, H. Kajitani, S. Bandoh, M. Tokuda et al., Lymphocyte subsets in lung tissues of interstitial pneumonia associated with untreated polymyositis/dermatomyositis, Rheumatol Int, vol.21, issue.3, pp.89-93, 2001.

T. Kotani, T. Takeuchi, S. Makino, K. Hata, S. Yoshida et al., Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia, Clin Rheumatol, vol.30, issue.8, pp.1021-1029, 2011.

A. Labirua-iturburu, A. Selva-o'callaghan, X. Martínez-gómez, E. Trallero-araguás, M. Labrador-horrillo et al., Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease, Clin Exp Rheumatol, vol.31, issue.3, pp.436-445, 2013.

L. Cavagna, R. Caporali, L. Abdì-alì, R. Dore, F. Meloni et al., Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease, J Rheumatol, vol.40, issue.4, pp.484-92, 2013.

C. V. Oddis and R. Aggarwal, Treatment in myositis, Nat Rev Rheumatol, 2018.

Y. Vanrenterghem, L. Roels, T. Lerut, J. Gruwez, P. Michielsen et al.,

, Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients, Lancet Lond Engl, vol.1, issue.8436, pp.999-1002, 1985.

A. Innes, P. A. Rowe, M. C. Foster, M. J. Steiger, and A. G. Morgan, Cyclosporin toxicity and colitis, Lancet Lond Engl, vol.2, issue.8617, p.957, 1988.

S. J. Fishman, L. J. Wylonis, J. D. Glickman, J. J. Cook, D. S. Warsaw et al.,

, Cyclosporin A augments human platelet sensitivity to aggregating agents by increasing fibrinogen receptor availability, J Surg Res, vol.51, issue.2, pp.93-101, 1991.

T. Bombeli, M. Müller, P. W. Straub, and A. Haeberli, Cyclosporine-induced detachment of vascular endothelial cells initiates the intrinsic coagulation system in plasma and whole blood, J Lab Clin Med, vol.127, issue.6, pp.621-655, 1996.

R. Mroz, M. Korniluk, and E. Chyczewska, Dermatomyositis masquerading as pulmonary embolism, Eur J Med Res, vol.14, issue.4, pp.162-166, 2009.

M. Benzaquen, F. Rouby, M. Bobot, D. Lebowitz, J. Serratrice et al., Pulmonary embolism induced by methotrexate in a dermatomyositis patient, Joint Bone Spine, vol.84, issue.4, pp.501-503, 2017.

I. M. Bronner, M. Van-der-meulen, W. Linssen, J. E. Hoogendijk, and M. De-visser,

J. Murgi?, M. Prpi?, I. Kirac, A. Camino-varela, A. Bolanca et al.,

, Dermatomyositis as paraneoplastic syndrome of peritoneal and ovarian relapse after longterm complete remission in patient with metastatic bilateral breast cancer, Coll Antropol, vol.36, issue.1, pp.325-334, 2012.

Y. Takagi, K. Hagiwara, T. Sato, O. Akiyama, T. Ogura et al., Massive pulmonary thromboembolism found at autopsy in a patient with a 14-year history of polymyositis-associated nonspecific interstitial pneumonia

, Nihon Kokyuki Gakkai Zasshi, vol.46, issue.10, pp.808-821, 2008.

M. Bando, H. Yamada, K. Kusunose, S. Hayashi, Y. Takagawa et al., Pulmonary embolism due to right atrial free-floating thrombus during echocardiographic examination: a case of a pulmonary saddle thrombus, J Echocardiogr, vol.13, issue.4, pp.145-152, 2015.

V. Foris, G. Kovacs, M. Matucci-cerinic, and H. Olschewski, PL-7 Positive Antisynthetase Syndrome and Pulmonary Hypertension, J Rheumatol, vol.40, issue.10, pp.1777-1786, 2013.

M. B. Jones, R. K. Osterholm, R. B. Wilson, F. H. Martin, J. R. Commers et al., Fatal pulmonary hypertension and resolving immune-complex glomerulonephritis in mixed connective tissue disease. A case report and review of the literature, Am J Med, vol.65, issue.5, pp.855-63, 1978.

N. Ueda, K. Mimura, H. Maeda, T. Sugiyama, T. Kado et al., Mixed connective tissue disease with fatal pulmonary hypertension and a review of literature, Virchows Arch A Pathol Anat Histopathol, vol.404, issue.4, pp.335-375, 1984.

Y. Saito, K. Orikasa, K. Saito, T. Nishimaki, T. Morito et al., An autopsy case of patient with mixed connective tissue disease with pulmonary hypertension and a remarkable thrombus in pulmonary truncus

, Nihon Naika Gakkai Zasshi J Jpn Soc Intern Med, vol.78, issue.3, pp.440-441, 1989.

Y. Ueda, Y. Yamauchi, K. Makizumi, R. Kaji, H. Ishibashi et al., Successful treatment of acute right cardiac failure due to pulmonary thromboembolism in mixed connective tissue disease, Jpn J Med, vol.30, issue.6, pp.568-72, 1991.

R. Kasten, G. Pfirrmann, and V. Voigtländer, Klinefelter's syndrome associated with mixed connective tissue disease (Sharp's syndrome) and thrombophilia with postthrombotic syndrome

, J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG, vol.3, issue.8, pp.623-629, 2005.

M. L. Jensen, J. M. Wieting, M. T. Andary, M. J. Fankhauser, and M. J. Jones, Inclusion body myositis and transitional cell carcinoma of the bladder: significant resolution of symptoms after tumor excision, Arch Phys Med Rehabil, vol.78, issue.3, pp.327-336, 1997.

M. Wittstock, R. Benecke, and U. K. Zettl, Therapy with Intravenous Immunoglobulins: Complications and Side-Effects, Eur Neurol, vol.50, issue.3, pp.172-177, 2003.

S. Lakhanpal, J. T. Lie, D. L. Conn, and W. J. Martin, Pulmonary disease in polymyositis/dermatomyositis: a clinicopathological analysis of 65 autopsy cases, Ann Rheum Dis, vol.46, issue.1, pp.23-32, 1987.

R. R. Patel, V. N. Iyer, and J. H. Ryu, CAUSES OF DEATH IN 34 CONSECUTIVE AUTOPSY CASES OF POLYMYOSITIS/DERMATOMYOSITIS. CHEST, vol.134, p.126, 2008.

F. Maldonado, R. R. Patel, V. N. Iyer, E. S. Yi, and J. H. Ryu, Are respiratory complications common causes of death in inflammatory myopathies? An autopsy study, Respirology, vol.17, issue.3, pp.455-60, 2012.

M. Wodkowski, M. Hudson, S. Proudman, J. Walker, W. Stevens et al., Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects, Autoimmunity, vol.48, issue.8, pp.542-51, 2015.

T. E. Lloyd, A. L. Mammen, A. A. Amato, M. D. Weiss, M. Needham et al., Evaluation and construction of diagnostic criteria for inclusion body myositis, Neurology, vol.83, issue.5, pp.426-459, 2014.

L. Gallay and P. Petiot, Sporadic inclusion-body myositis: Recent advances and the state of the art in 2016, Rev Neurol, vol.172, issue.10, pp.581-587, 2016.

O. Benveniste, W. Stenzel, and Y. Allenbach, Advances in serological diagnostics of inflammatory myopathies, Curr Opin Neurol, vol.29, issue.5, pp.662-73, 2016.

P. D. Stein, J. Goldman, F. Matta, and A. Y. Yaekoub, Diabetes mellitus and risk of venous thromboembolism, Am J Med Sci, vol.337, issue.4, pp.259-64, 2009.

J. A. Heit, C. L. Leibson, A. A. Ashrani, T. M. Petterson, K. R. Bailey et al., Is Diabetes Mellitus an Independent Risk Factor for Venous Thromboembolism? A Population-Based Case-Control Study, Arterioscler Thromb Vasc Biol, vol.29, issue.9, pp.1399-405, 2009.

E. J. Bell, A. R. Folsom, P. L. Lutsey, E. Selvin, N. A. Zakai et al., Diabetes mellitus and venous thromboembolism: A systematic review and meta-analysis, Diabetes Res Clin Pract, vol.111, pp.10-18, 2016.

D. Stuijver, B. Van-zaane, E. Romualdi, D. Brandjes, V. Gerdes et al., The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: a systematic review and meta-analysis, Thromb Haemost, vol.108, issue.6, pp.1077-88, 2012.

S. C. Kim, S. Schneeweiss, J. Liu, and D. H. Solomon, Risk of venous thromboembolism in patients with rheumatoid arthritis, Arthritis Care Res, vol.65, issue.10, pp.1600-1607, 2013.

W. Chung, C. Peng, C. Lin, Y. Chang, Y. Chen et al., Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study, Ann Rheum Dis, vol.73, issue.10, pp.1774-80, 2014.

P. Ungprasert, N. Srivali, I. Spanuchart, C. Thongprayoon, and E. L. Knight, Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and metaanalysis, Clin Rheumatol, vol.33, issue.3, pp.297-304, 2014.

C. F. Christiansen, Risk of vascular disease in patients with multiple sclerosis: a review, Neurol Res, vol.34, issue.8, pp.746-53, 2012.

W. Chung, C. Lin, T. Tsai, W. Hsu, and C. Kao, Multiple sclerosis increases the risk of venous thromboembolism: a nationwide cohort analysis, Eur J Clin Invest, vol.45, issue.12, pp.1228-1261, 2015.

P. Peeters, M. T. Bazelier, B. Uitdehaag, H. Leufkens, D. Bruin et al., The risk of venous thromboembolism in patients with multiple sclerosis: the Clinical Practice Research Datalink, J Thromb Haemost JTH, vol.12, issue.4, pp.444-51, 2014.

C. N. Bernstein, J. F. Blanchard, D. S. Houston, and A. Wajda, The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study, Thromb Haemost, vol.85, issue.3, pp.430-434, 2001.

M. D. Kappelman, E. Horvath-puho, R. S. Sandler, D. T. Rubin, T. A. Ullman et al., Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study, Gut, vol.60, issue.7, pp.937-980, 2011.

H. Yuhara, C. Steinmaus, D. Corley, J. Koike, M. Igarashi et al., Metaanalysis: the risk of venous thromboembolism in patients with inflammatory bowel disease, Aliment Pharmacol Ther, vol.37, issue.10, pp.953-62, 2013.

O. Ahlehoff, G. H. Gislason, J. Lindhardsen, M. G. Charlot, C. H. Jørgensen et al., Psoriasis Carries an Increased Risk of Venous Thromboembolism: A Danish Nationwide Cohort Study, PLOS ONE, vol.6, issue.3, p.18125, 2011.

P. L. Lutsey, A. E. Prizment, and A. R. Folsom, Psoriasis is associated with greater risk of incident venous thromboembolism: The Iowa Women's Health Study, J Thromb Haemost, vol.10, issue.4, pp.708-719, 2012.

P. Ungprasert, A. Sanguankeo, S. Upala, and P. Suksaranjit, Psoriasis and risk of venous thromboembolism: a systematic review and meta-analysis, QJM Int J Med, vol.107, issue.10, pp.793-800, 2014.

J. F. Ludvigsson, A. Welander, R. Lassila, A. Ekbom, and S. M. Montgomery, Risk of thromboembolism in 14 000 individuals with coeliac disease, Br J Haematol, vol.139, issue.1, pp.121-128, 2007.

A. Lerner and M. Blank, Hypercoagulability in celiac disease-an update, Autoimmun Rev, vol.13, issue.11, pp.1138-1179, 2014.

P. Ungprasert, K. Wijarnpreecha, and P. Tanratana, Risk of venous thromboembolism in patients with celiac disease: A systematic review and meta-analysis, J Gastroenterol Hepatol, vol.31, issue.7, pp.1240-1245, 2016.

W. Chung, C. Lin, F. Sung, W. Hsu, Y. Chen et al., Increased risks of deep vein thrombosis and pulmonary embolism in Sjögren syndrome: a nationwide cohort study, J Rheumatol, vol.41, issue.5, pp.909-924, 2014.

J. J. Lee and J. E. Pope, A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases, Arthritis Res Ther, vol.16, issue.5, 2014.

P. Ungprasert, N. Srivali, and W. Kittanamongkolchai, Risk of venous thromboembolism in patients with Sjögren's syndrome: a systematic review and meta-analysis, Clin Exp Rheumatol, vol.33, issue.5, pp.746-50, 2015.

P. E. Love and S. A. Santoro, Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance, Ann Intern Med, vol.112, issue.9, pp.682-98, 1990.

A. Cogo, E. Bernardi, P. Prandoni, B. Girolami, F. Noventa et al., Acquired risk factors for deep-vein thrombosis in symptomatic outpatients, Arch Intern Med, vol.154, issue.2, pp.164-172, 1994.

R. Cervera, M. A. Khamashta, J. Font, G. D. Sebastiani, A. Gil et al., Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1, 2003.

P. I. Burgos, G. Mcgwin, J. D. Reveille, L. M. Vilá, and G. S. Alarcón, Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII). Rheumatol Oxf Engl, vol.49, pp.1720-1725, 2010.

M. C. Dalakas, Inflammatory Muscle Diseases, N Engl J Med, vol.372, issue.18, pp.1734-1781, 2015.

I. E. Lundberg, F. W. Miller, A. Tjärnlund, and M. Bottai, Diagnosis and classification of Idiopathic Inflammatory Myopathies, J Intern Med, vol.280, issue.1, pp.39-51, 2016.

T. A. Medsger, W. N. Dawson, and A. T. Masi, The epidemiology of polymyositis, Am J Med

A. Bohan and J. B. Peter, Polymyositis and dermatomyositis (first of two parts), N Engl J Med, vol.292, issue.7, pp.344-351, 1975.

A. Bohan and J. B. Peter, Polymyositis and dermatomyositis (second of two parts), N Engl J Med, vol.292, issue.8, pp.403-410, 1975.

J. B. Lilleker, J. Vencovsky, G. Wang, L. R. Wedderburn, L. P. Diederichsen et al., The EuroMyositis registry: an international collaborative tool to facilitate myositis research, Ann Rheum Dis, vol.77, issue.1, pp.30-39, 2018.

S. Carpenter, G. Karpati, I. Heller, and A. Eisen, Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy, Neurology, vol.28, issue.1, pp.8-17, 1978.

M. C. Dalakas, Polymyositis, dermatomyositis and inclusion-body myositis, N Engl J Med, vol.325, issue.21, pp.1487-98, 1991.

R. C. Griggs, V. Askanas, S. Dimauro, A. Engel, G. Karpati et al., Inclusion body myositis and myopathies, Ann Neurol, vol.38, issue.5, pp.705-718, 1995.

I. N. Targoff, F. W. Miller, T. A. Medsger, C. Oddis, M. Van-der-meulen et al., Classification criteria for the idiopathic inflammatory myopathies, Curr Opin Rheumatol, vol.9, issue.6, pp.316-337, 1997.

J. E. Hoogendijk, A. A. Amato, B. R. Lecky, E. H. Choy, I. E. Lundberg et al., 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, Neuromuscul Disord NMD, vol.14, issue.5, pp.337-382, 2003.

G. Hengstman, H. J. Ter-laak, V. Egberts, W. Lundberg, I. E. Moutsopoulos et al.,

J. Vencovsky, Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy, Ann Rheum Dis, vol.65, issue.12, pp.1635-1643, 2006.

A. L. Mammen, T. Chung, L. Christopher-stine, P. Rosen, A. Rosen et al.,

, Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy, Arthritis Rheum, vol.63, issue.3, pp.713-734, 2011.

Y. Troyanov, I. N. Targoff, J. Tremblay, J. Goulet, Y. Raymond et al., Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients, Medicine, 2005.

G. R. Connors, L. Christopher-stine, C. V. Oddis, and S. K. Danoff, Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest, vol.138, pp.1464-74, 2010.

S. Jablonska and M. Blaszczyk, Scleromyositis: a scleroderma/polymyositis overlap syndrome, Clin Rheumatol, vol.17, issue.6, pp.465-472, 1998.

I. E. Lundberg, A. Tjärnlund, M. Bottai, V. P. Werth, C. Pilkington et al.,

, European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups, Ann Rheum Dis, vol.76, issue.12, pp.1955-64, 2017.

Y. Allenbach, O. Benveniste, H. Goebel, and W. Stenzel, Integrated classification of inflammatory myopathies, Neuropathol Appl Neurobiol, vol.43, issue.1, pp.62-81, 2017.

A. Meyer, B. Lannes, J. Goetz, A. Echaniz-laguna, D. Lipsker et al., Inflammatory myopathies: A new landscape, Joint Bone Spine, vol.85, issue.1, pp.23-33, 2018.

A. B. Robinson and A. M. Reed, Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis, Nat Rev Rheumatol, vol.7, issue.11, pp.664-75, 2011.

J. M. Olazagasti, P. J. Baez, D. A. Wetter, and F. C. Ernste, Cancer risk in dermatomyositis: a meta-analysis of cohort studies, Am J Clin Dermatol, vol.16, issue.2, pp.89-98, 2015.

M. Needham and F. L. Mastaglia, Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches, Lancet Neurol, vol.6, issue.7, pp.620-651, 2007.

P. Basharat and L. Christopher-stine, Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management, Curr Rheumatol Rep, vol.17, issue.12, p.72, 2015.

M. Tateyama, K. Fujihara, T. Misu, A. Arai, T. Kaneta et al., Clinical values of FDG PET in polymyositis and dermatomyositis syndromes: imaging of skeletal muscle inflammation, BMJ Open, vol.5, issue.1, p.6763, 2015.

A. Al-nahhas and A. Jawad, PET/CT imaging in inflammatory myopathies, Ann N Y Acad Sci, vol.1228, pp.39-45, 2011.

A. Meyer, N. Meyer, M. Schaeffer, J. Gottenberg, B. Geny et al., Incidence and prevalence of inflammatory myopathies: a systematic review, Rheumatol Oxf Engl, vol.54, issue.1, pp.50-63, 2015.

A. Imbert-masseau, M. Hamidou, C. Agard, J. Grolleau, and P. Chérin, Antisynthetase syndrome, Joint Bone Spine, vol.70, issue.3, pp.161-169, 2003.

C. Quinn, J. S. Salameh, T. Smith, and N. Souayah, Necrotizing myopathies: an update, J Clin Neuromuscul Dis, vol.16, issue.3, pp.131-171, 2015.

D. J. Graham, J. A. Staffa, D. Shatin, S. E. Andrade, S. D. Schech et al., Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs, JAMA, vol.292, issue.21, pp.2585-90, 2004.

F. C. Wilson, S. R. Ytterberg, S. Sauver, J. L. Reed, and A. M. , Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota, J Rheumatol, vol.35, issue.3, pp.445-452, 2008.

R. L. Leff, S. H. Burgess, F. W. Miller, L. A. Love, I. N. Targoff et al., Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with antiJo-1 and anti-signal recognition particle autoantibodies, Arthritis Rheum, vol.34, issue.11, pp.1391-1397, 1991.

O. S. Morgan, P. Rodgers-johnson, C. Mora, and G. Char, HTLV-1 and polymyositis in Jamaica, Lancet Lond Engl, vol.2, issue.8673, pp.1184-1191, 1989.

M. L. Christensen, L. M. Pachman, R. Schneiderman, D. C. Patel, and J. M. Friedman, Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis, Arthritis Rheum, vol.29, issue.11, pp.1365-70, 1986.

R. L. Leff, L. A. Love, F. W. Miller, S. J. Greenberg, E. A. Klein et al., Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle, Lancet Lond Engl, vol.339, issue.8803, pp.1192-1197, 1992.

M. B. Mathews and R. M. Bernstein, Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity, Nature, vol.304, issue.5922, pp.177-186, 1983.

L. J. Albert and R. D. Inman, Molecular Mimicry and Autoimmunity, N Engl J Med, 1999.

, Dec, vol.30, issue.27, pp.2068-74

E. J. Walker and P. D. Jeffrey, Polymyositis and molecular mimicry, a mechanism of autoimmunity, Lancet Lond Engl, vol.2, issue.8507, pp.605-612, 1986.

A. Ponyi, T. Constantin, M. Garami, C. András, B. Tállai et al., Cancerassociated myositis: clinical features and prognostic signs, Ann N Y Acad Sci, vol.1051, pp.64-71, 2005.

E. Tiniakou and A. L. Mammen, Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review, Clin Rev Allergy Immunol, vol.52, issue.1, pp.20-33, 2017.

Y. Muro, K. Sugiura, M. Nara, I. Sakamoto, N. Suzuki et al., High incidence of cancer in anti-small ubiquitin-like modifier activating enzyme antibody-positive dermatomyositis, Rheumatol Oxf Engl, vol.54, issue.9, pp.1745-1752, 2015.

H. Yang, Q. Peng, L. Yin, S. Li, J. Shi et al., Identification of multiple cancerassociated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study, Arthritis Res Ther, vol.19, issue.1, 2017.

J. C. Milisenda, Tumour TIF1 mutations and loss of heterozygosity related to cancerassociated myositis. Rheumatol Oxf Engl, vol.57, pp.388-96, 2018.

L. Casciola-rosen, K. Nagaraju, P. Plotz, K. Wang, S. Levine et al., Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy, J Exp Med, vol.201, issue.4, pp.591-601, 2005.

A. L. Mammen, Statin-Associated Autoimmune Myopathy, N Engl J Med, vol.374, issue.7, pp.664-673, 2016.

A. Lafuma, F. Fagnani, F. Peltier-pujol, and A. Rauss,

, J Mal Vasc, vol.19, issue.3, pp.185-194, 1994.

A. Cogo, E. Bernardi, P. Prandoni, B. Girolami, F. Noventa et al., Acquired risk factors for deep-vein thrombosis in symptomatic outpatients, Arch Intern Med, vol.154, issue.2, pp.164-172, 1994.

S. V. Ramagopalan, C. J. Wotton, A. E. Handel, D. Yeates, and M. J. Goldacre, Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study, BMC Med, vol.9, p.1, 2011.

B. Zöller, X. Li, J. Sundquist, and K. Sundquist, Autoimmune diseases and venous thromboembolism: a review of the literature, Am J Cardiovasc Dis, vol.2, issue.3, pp.171-83, 2012.

S. A. Johannesdottir, M. Schmidt, E. Horváth-puhó, and H. T. Sørensen, Autoimmune skin and connective tissue diseases and risk of venous thromboembolism: a population-based casecontrol study, J Thromb Haemost JTH, vol.10, issue.5, pp.815-836, 2012.

W. Chung, C. Lin, F. Sung, C. Lu, and C. Kao, Increased risk of venous thromboembolism in patients with dermatomyositis/polymyositis: a nationwide cohort study, Thromb Res, vol.134, issue.3, pp.622-628, 2014.

N. Bleau, V. Patenaude, and H. A. Abenhaim, Risk of Venous Thromboembolic Events in Pregnant Patients With Autoimmune Diseases: A Population-Based Study, Clin Appl Thromb Off J Int Acad Clin Appl Thromb, vol.22, issue.3, pp.285-91, 2016.

E. C. Carruthers, H. K. Choi, E. C. Sayre, and J. A. Aviña-zubieta, Risk of Deep Venous Thrombosis and Pulmonary Embolism in Individuals with Polymyositis and Dermatomyositis: A General Population-Based Study, Ann Rheum Dis, vol.75, issue.1, p.110, 2016.

A. Antovic, A. Notarnicola, J. Svensson, I. E. Lundberg, and M. Holmqvist, Venous thromboembolic events in idiopathic inflammatory myopathy-occurrence and relation to disease onset, Arthritis Care Res, 2018.

S. D. Gaitonde and S. P. Ballou, Deep venous thrombosis in dermatomyositis, J Rheumatol

A. Selva-o'callaghan, A. Fernández-luque, X. Martínez-gómez, A. Labirua-iturburu, and M. Vilardell-tarrés, Venous thromboembolism in patients with dermatomyositis and polymyositis, Clin Exp Rheumatol, vol.29, issue.5, pp.846-855, 2011.

, polymyosite (PM), syndrome des anti-synthétases (SAS), scleromyosite (SCM), myosite à inclusions (MI) et myopathie nécrosante auto-immune (MNAI). Plusieurs études épidémiologiques ont démontré un risque plus élevé de maladie thromboembolique veineuse (MTEV), RÉSUMÉ Introduction. Les myopathies inflammatoires idiopathiques (MII) sont des pathologies hétérogènes caractérisées par une faiblesse des muscles striés squelettiques et une inflammation musculaire. Les MII peuvent être classées en dermatomyosite (DM)

, Cependant, ces études ne différenciaient que les DM et les PM, sans tenir compte des nouveaux sousgroupes, et les facteurs de risque de MTEV n'étaient pas pris en compte. Objectif : Identifier les facteurs de risque spécifiques de survenue de MTEV dans les MII

C. E. Metz, . Durkheim, . Epinal, . Ch-jeanne-d'arc, C. Bar-le-duc et al., Le délai de survenue était en moyenne de 4,7 ans dont 34,7% durant la première année suivant le diagnostic. L'immobilisation (20%), une infection (10%), une néoplasie (20%), une myosite active (31%), l'utilisation d'immunoglobulines intraveineuses (17%) et de corticoïdes (55%) étaient retrouvés au diagnostic de MTEV. En analyse univariée, la survenue d'une MTEV était associée à un âge plus élevé, à un antécédent de MTEV, à une dysphonie ainsi qu'à un recours plus fréquent à la ciclosporine. Les patients présentant une MTEV avaient reçu un plus grand nombre de lignes thérapeutiques. La comparaison de la survie sans thrombose entre deux clusters de myosites, Etude : Tous les adultes présentant une MII, hospitalisés au moins une fois dans un service de médecine interne des 5 hôpitaux de la région Grand Est

, Nous avons retrouvé des facteurs de risque connus de thrombose, ainsi que des facteurs en lien avec la sévérité de la maladie. Le sous-groupe de MII semble influencer ce risque de MTEV, avec l'identification de clusters de patients plus à risque. Ces patients pourraient bénéficier de mesures prophylactiques adaptées, Conclusion : Le risque de MTEV est accru les myopathies inflammatoires

T. En-anglais, Risk factors of venous thromboembolism in idiopathic inflammatory myopathies. THÈSE : Médecine Spécialisée-Année, 2018.

, embolie pulmonaire, thrombose veineuse profonde, maladie thromboembolique veineuse, dermatomyosite, polymyosite, syndrome des anti-synthétases, syndrome de chevauchement, myopathie nécrosante auto-immune, scléromyosite, MOTS CLEFS : myosites, myopathies inflammatoires idiopathiques, thrombose